Lion Point Capital, LP Portfolio Holdings

Lion Point Capital, LP

  • $37.2 Million
  • Q3 2024

Lion Point Capital, LP has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $37.2 Million distributed in 25 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Insmed Inc with a value of $3.81M, Geron Corp with a value of $2.86M, Ardelyx, Inc. with a value of $2.55M, Milestone Pharmaceuticals Inc. with a value of $2.51M, and Bridge Bio Pharma, Inc. with a value of $1.25M.

Examining the 13F form we can see an decrease of $9.49M in the current position value, from $46.7M to 37.2M.

Lion Point Capital, LP is based out at New York, NY

Below you can find more details about Lion Point Capital, LP portfolio as well as his latest detailed transactions.

Portfolio value $37.2 Million
Healthcare: $19 Million
ETFs: $18.2 Million
Technology: $43,000
Communication Services: $16,000

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$9.85B
$3.81 Million 10.23% of portfolio
52,200
Q3 2024 Reduced 25.78%
$1.51B
$2.86 Million 7.68% of portfolio
630,000
Q2 2024 Added 5.0%
$761M
$2.55 Million 6.84% of portfolio
370,000
Q3 2024 Reduced 56.81%
$55.8M
$2.51 Million 6.75% of portfolio
1,654,154
Q3 2024 Reduced 29.32%
$3.42B
$1.25 Million 3.35% of portfolio
49,000
Q2 2024 New
$121M
$1.08 Million 2.89% of portfolio
215,000
Q3 2024 Added 26.47%
$902M
$889,000 2.39% of portfolio
46,200
Q3 2024 Reduced 28.92%
$23.1M
$820,000 2.2% of portfolio
1,578,256
Q3 2024 Added 132.69%
$416M
$605,000 1.62% of portfolio
57,750
Q3 2024 Added 59.31%
$613M
$326,000 0.88% of portfolio
35,100
Q3 2024 New
$100M
$323,000 0.87% of portfolio
340,761
Q4 2023 Reduced 50.74%
$36.3M
$153,000 0.41% of portfolio
39,589
Q3 2024 Reduced 56.4%
$3.1T
$43,000 0.12% of portfolio
100
Q3 2022 New
$11.8M
$35,000 0.09% of portfolio
75,000
Q1 2024 New
$1.08T
$16,000 0.04% of portfolio
100
Q1 2023 New
Kiniksa Pharmaceuticals LTD
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 41.35%
Avadel Pharmaceuticals PLC
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 22.42%
Mineralys Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2024 Added 31.67%
Benitec Biopharma Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Biohaven LTD
-
$0 0.0% of portfolio
-
Q3 2024 New
Disc Medicine Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Marinus Pharmaceuticals Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 67.19%

Summary

  • Portfolio
  • No. of Stocks 25
  • Current Value $37.2 Million
  • Prior Value $46.7 Million
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 4 stocks
  • Additional Purchases 3 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 8 stocks
Track This Portfolio

Track Lion Point Capital, LP Portfolio

Follow Lion Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lion Point Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email